University of Cambridge

Nuclera secures $75 million to commercialize its eProtein Discovery™ benchtop system, designed to accelerate protein expression and purification, reducing time and cost. The system is already in use at leading research institutions and biotech companies.

César Milstein, an Argentinian scientist, was awarded the 1984 Nobel Prize in Medicine for developing monoclonal antibodies with George J. Köhler and Niels K. Jerne. Milstein's work at Cambridge revolutionized medicine, leading to treatments for cancer, autoimmune diseases, and organ transplant rejection.

The Eppendorf Award for Young European Investigators, in collaboration with Nature, accepts applications from October 1, 2024 to January 15, 2025. Open to scientists aged 35 and under with an advanced degree conducting research in Europe. The winner will be selected by an independent jury chaired by Laura Machesky (University of Cambridge, UK).

AI in healthcare includes reducing documentation burdens, improving diagnostics, predicting outcomes, analyzing datasets, customizing treatments, and speeding up clinical trial recruitment. Institutions like OSF HealthCare and University of Chicago Medicine are exploring AI for tasks like drafting clinical notes and detecting diseases. Ethical oversight involves strategic priorities, stakeholder involvement, cost-benefit analysis, and continuous monitoring. AI aims to improve quality, accessibility, equity, and patient experience, though challenges remain in transparency and understanding AI's complex processes.

Host-microbial interactions in barrier tissues, like oral mucosa and skin, are crucial for immune regulation. Epithelial cells, key players in immune defense, interact with microbial elements, contributing to tissue-specific immunity. This webcast presents leading studies on these mechanisms, offering insights into health and disease, and the challenges in mapping complex cellular environments. Essential for scientists and clinicians interested in structural immunity and advanced spatial biology techniques.

Recent acquisitions of cancer drug developers RayzeBio and Fusion Pharmaceuticals highlight radiotherapy's resurgence. Oncology sees advancements in genetics, immunology, AI, and personalized treatments. Funding remains robust, with potential for highest corporate rounds since 2021. Combination therapies and AI are crucial, with cancer vaccines and precision treatments offering hope. Despite challenges, progress in treating specific cancers has improved patient outcomes.

Damage to the brainstem, identified in Long COVID patients via 7-Tesla MRI scans, could explain physical and psychological symptoms like breathlessness, fatigue, and anxiety. Researchers from the University of Cambridge suggest that inflammation in the brainstem following COVID-19 infection may be responsible for these long-lasting effects.

Wellcome Leap’s Quantum for Bio program advances teams to Phase 2, offering up to $750,000 for classical simulations of quantum algorithms in healthcare. Finalists include Infleqtion, University of Nottingham, qBraid Co., University of Copenhagen, Harvard University, Stanford University, Algorithmiq Inc., and University of Cambridge. Phase 3 offers up to $5 million for significant quantum advancements in healthcare.

Derek Cocker and colleagues advocate for innovative whole system approaches to integrate research and novel technologies within patient pathways to target antibiotic use, minimize healthcare-associated infections, and adapt to novel pathogens. They emphasize the need for system-wide analyses, optimized clinical trial design, and regulatory processes to generate rapid evidence on tackling infection threats. The article highlights the risks posed by patient pathways and calls for a shift to patient-centered care, seamless integration between healthcare settings, and better data sharing to protect patients, staff, and healthcare resilience.

HKGI and AZ discussed potential research collaborations to expedite clinical trials for new pharmaceuticals, aiming to foster innovations in genomic medicine and enhance local healthcare services.